WILMINGTON, Delaware, USA, April 28, 2026
AstraZeneca has announced that its fixed-dose triple-combination therapy Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) has received approval from the U.S. Food and Drug Administration for the maintenance treatment of asthma in patients aged 12 years and older, marking a major regulatory milestone in respiratory disease management. The approval establishes Breztri as the first and only single-inhaler triple therapy for asthma in the United States, expanding its clinical use beyond its earlier indication in chronic obstructive pulmonary disease (COPD). This decision is based on strong Phase III clinical evidence demonstrating significant improvements in lung function and rapid onset of action, reinforcing its potential to address the needs of millions of patients suffering from uncontrolled asthma.
FDA Approval Marks Breakthrough in Asthma Treatment
The FDA approval of Breztri represents a pivotal advancement in asthma therapy, particularly for patients who remain symptomatic despite standard dual-combination inhaler treatments. Asthma affects approximately 27 million people in the United States, with a substantial proportion experiencing inadequate disease control on existing therapies.
Breztri combines three mechanisms of action—inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA), and long-acting muscarinic antagonist (LAMA)—into a single inhaler, offering a more comprehensive approach to airway inflammation and bronchoconstriction. The therapy is designed as a maintenance treatment, meaning it is intended for long-term disease control rather than acute symptom relief, highlighting its role in improving baseline respiratory function and reducing exacerbation risks.
Phase III Trials Demonstrate Clinical Superiority
Advertisement
The regulatory approval is supported by data from the Phase III KALOS and LOGOS trials, which evaluated Breztri in a broad population of asthma patients, including those with and without recent exacerbations. These studies demonstrated statistically significant and clinically meaningful improvements in lung function compared to dual-combination ICS/LABA therapies, a current standard of care. Notably, Breztri showed a rapid improvement in lung function within five minutes of the first dose, underscoring its potential to deliver immediate clinical benefits alongside long-term disease control.
The trials also confirmed a favorable safety and tolerability profile, with no new safety concerns identified, further supporting its suitability for widespread clinical use. These findings highlight the growing importance of triple-combination therapies in optimizing respiratory outcomes and reducing disease burden.
Advancing Respiratory Care and Global Treatment Standards
The approval of Breztri for asthma reflects a broader shift toward integrated, multi-mechanism therapies that address the complex pathophysiology of chronic respiratory diseases. By consolidating three therapeutic components into a single inhaler, the treatment simplifies patient adherence while delivering enhanced clinical efficacy. From a cGxP perspective, the development and approval of Breztri demonstrate adherence to Good Clinical Practice (GCP), regulatory compliance, and robust quality standards, ensuring the reliability and reproducibility of clinical outcomes.
AstraZeneca continues to pursue regulatory approvals for the asthma indication in other global markets, including Europe, Japan, and China, which could further expand access to this innovative respiratory therapy. As healthcare systems increasingly focus on patient-centric, effective, and scalable treatment solutions, Breztri is expected to play a key role in shaping the future of asthma management and improving quality of life for patients worldwide.
Source: AstraZeneca press release
